Stephen Hahn, FDA commissioner (AP Images)

FDA touts ad­vanced man­u­fac­tur­ing to ad­dress Covid-19 short­falls

Anand Shah

Ad­vanced man­u­fac­tur­ing tech­niques can be em­ployed to help ad­dress some of the man­u­fac­tur­ing and sup­ply chain prob­lems the US has seen dur­ing the Covid-19 pan­dem­ic, Stephen Hahn, FDA com­mis­sion­er, and Anand Shah, FDA deputy com­mis­sion­er for med­ical and sci­en­tif­ic af­fairs, wrote in a blog post on the FDA web­site.

“The po­ten­tial pub­lic health val­ue of ad­vanced man­u­fac­tur­ing is even greater in the con­text of the on­go­ing COVID-19 pan­dem­ic, which has high­light­ed the strain on sup­ply chains and the need for adap­tive man­u­fac­tur­ing sys­tems to ac­cel­er­ate the pro­duc­tion of med­ical coun­ter­mea­sures,” Hahn and Shah wrote. “The FDA has es­tab­lished a strong reg­u­la­to­ry foun­da­tion to sup­port the up­take of ad­vanced man­u­fac­tur­ing, and COVID-19 pro­vides the unique im­pe­tus to spur fur­ther ad­vance­ment of med­ical man­u­fac­tur­ing.”

They high­light­ed key reg­u­la­tions the agency has pro­mul­gat­ed in re­cent years to sup­port ad­vanced man­u­fac­tur­ing, specif­i­cal­ly:

  • The Emerg­ing Tech­nol­o­gy Pro­gram un­der the Cen­ter for Drug Eval­u­a­tion and Re­search (CDER), which sup­ports com­pa­nies in de­vel­op­ing process con­trol mea­sures for con­tin­u­ous man­u­fac­tur­ing of drugs be­fore sub­mis­sion.
  • The Ad­vanced Tech­nolo­gies Team un­der the Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER) which sup­ports de­vel­op­ers by ad­dress­ing tech­ni­cal con­sid­er­a­tions need­ed to cre­ate gene ther­a­pies.
  • The de­vel­op­ment of “leapfrog” guid­ance doc­u­ments to share the agency’s think­ing on emerg­ing tech­nolo­gies that could be im­por­tant in pub­lic health emer­gen­cies. Such an­tic­i­pa­to­ry guid­ance sup­ports in­no­va­tors as they bring new tech­nolo­gies to health care.
  • Part­ner­ships and re­search to ex­pand knowl­edge sur­round­ing ad­vanced man­u­fac­tur­ing.

Ad­di­tion­al ef­forts have been un­der­tak­en dur­ing the cur­rent pub­lic health emer­gency, Hahn and Shah point­ed out. A mul­ti­year ef­fort be­tween CDER and the US Bio­med­ical Ad­vanced Re­search and De­vel­op­ment Au­thor­i­ty (BAR­DA) is look­ing at how con­tin­u­ous man­u­fac­tur­ing process­es can sup­port the pro­duc­tion of med­ical coun­ter­mea­sures. Fur­ther, the FDA Of­fice of the Chief Sci­en­tist (OCS) and the Cen­ter for De­vices and Ra­di­o­log­i­cal Health (CDRH) are work­ing with the Na­tion­al In­sti­tutes of Health and the De­part­ments of Vet­er­ans Af­fairs to share in­for­ma­tion on 3D print­ing stan­dards to in­crease the stock of es­sen­tial med­ical sup­plies in­clud­ing per­son­al pro­tec­tive equip­ment and cer­tain med­ical de­vice parts.

FDA al­so is work­ing with­in the In­ter­na­tion­al Coun­cil for Har­mo­niza­tion to make sure that con­tin­u­ous man­u­fac­tur­ing guid­ances are aligned in­ter­na­tion­al­ly to sup­port in­no­va­tors, Hahn and Shah wrote.

“Be­cause pan­demics by na­ture are un­pre­dictable, our ap­proach to man­u­fac­tur­ing must be adapt­able. Ad­vanced man­u­fac­tur­ing pro­vides an ap­proach for pro­tect­ing our sup­ply chain and im­prov­ing our re­sponse ca­pac­i­ty dur­ing cri­sis sit­u­a­tions,” they con­clud­ed. “By es­tab­lish­ing the reg­u­la­to­ry foun­da­tion, the FDA has cre­at­ed a path­way for in­dus­try to con­tin­ue adopt­ing the need­ed im­prove­ments in man­u­fac­tur­ing tech­nol­o­gy for the ben­e­fit of pub­lic health.”

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA has vowed not to let politics overrule science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped the FDA and other health agencies under his purview of their rule making ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

President Donald Trump (via AP Images)

Signs of an 'Oc­to­ber Vac­cine Sur­prise' alarm ca­reer sci­en­tists

President Donald Trump, who seems intent on announcing a COVID-19 vaccine before Election Day, could legally authorize a vaccine over the objections of experts, officials at the FDA and even vaccine manufacturers, who have pledged not to release any vaccine unless it’s proved safe and effective.

In podcasts, public forums, social media and medical journals, a growing number of prominent health leaders say they fear that Trump — who has repeatedly signaled his desire for the swift approval of a vaccine and his displeasure with perceived delays at the FDA — will take matters into his own hands, running roughshod over the usual regulatory process.

Anthony Fauci (AP Images)

A press of­fi­cer at An­tho­ny Fau­ci’s NI­AID was un­masked as a hard-right Covid troll. He just re­tired to­day

William B Crews had been a public affairs specialist at the NIH’s National Institute of Allergy and Infectious Diseases.

That ended today when he informed the agency of his decision to retire, after he was identified as the managing editor at RedState, a prominent Trump loyalist website.

Crews’ RedState duties are performed under the alias streiff. While enjoying the benefits of pseudonymity, he disparaged and worked against NIAID with an incendiary level of rhetoric in the midst of a pandemic.

#ES­MO20: Push­ing in­to front­line, Mer­ck and Bris­tol My­ers duke it out with new slate of GI can­cer da­ta

Having worked in parallel for years to move their respective PD-1 inhibitors up to the first-line treatment of gastrointestinal cancers, Merck and Bristol Myers Squibb finally have the data at ESMO for a showdown.

Comparing KEYNOTE-590 and CheckMate-649, of course, comes with the usual caveats. But a side-by-side look at the overall survival numbers also offer some perspective on a new frontier for the reigning checkpoint rivals, both of whom are claiming to have achieved a first.

Donald Trump, AP

Covid-19 roundup: Trump sug­gests Pfiz­er vac­cine could be first ap­proved; VBI Vac­cines inks de­vel­op­ment deal with Cana­da

President Donald Trump commented Monday morning that Pfizer’s Covid-19 vaccine candidate could be the first to win approval by regulators.

During an interview on a Fox News’ morning show, the president said Pfizer was doing “very well” when asked which candidate could be approved, according to a Reuters report. He added that J&J could follow up afterward, saying “they’ll probably be a little later.”

UP­DAT­ED: Two wild weeks for Grail end in $8B Il­lu­mi­na buy­out

Grail’s whirlwind two weeks have ended in the wealthy arms of its former founder and benefactors.

Illumina has shelled out $8 billion to reacquire the closely-watched liquid biopsy startup they spun out just 5 years ago and sold off much of its shares just 3 years ago. The deal comes nearly two weeks after the well-heeled startup filed for a potentially massive IPO — one that was disrupted just a week later when Bloomberg reported that Illumina was in talks to buy their former spinout for up to $8 billion.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca pub­lish­es Covid-19 vac­cine PhI­II pro­to­cols in lock­step with Mod­er­na and Pfiz­er. How are they dif­fer­ent?

Following in the steps of Moderna and Pfizer, the other two American drugmakers currently in Phase III trials for their Covid-19 vaccines, AstraZeneca posted its own study protocols over the weekend. The move is the latest in a series of rare peeks behind the curtain, as such blueprints are typically shared once such trials are completed.

“Given the unprecedented global impact of the Coronavirus pandemic and the need for public information, AstraZeneca has published the detailed protocol and design of our AZD1222 clinical trial. As with most clinical development, protocols are not typically shared publicly due to the importance of maintaining confidentiality and integrity of trials. AstraZeneca continues to work with industry peers to ensure a consistent approach to sharing timely clinical trial information,” the company said in a statement.

Roche vaults to the front of the NL­RP3 clin­i­cal race, pay­ing $448M up­front to bag In­fla­zome

Roche is going all in on NLRP3.

The pharma giant is putting down $448 million (€380 million) upfront to snatch Novartis-backed Inflazome, which makes it a clinical player in the space overnight.

Dublin and Cambridge, UK-based Inflazome is the second NLRP3-focused biotech Roche has acquired in less than two years, and although no numbers were disclosed in the Jecure buyout, this is almost certainly a much larger deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Bris­tol My­ers marks Op­di­vo's sec­ond ad­ju­vant win — eye­ing a stan­dard of care gap

Moving into earlier and earlier treatment lines, Bristol Myers Squibb is reporting that adjuvant treatment with Opdivo has doubled the time that esophageal or gastroesophageal junction cancer patients stay free of disease.

With the CheckMate-577 data at ESMO, CMO Samit Hirawat said, the company believes it can change the treatment paradigm.

While a quarter to 30% of patients typically achieve a complete response following chemoradiation therapy and surgery, the rest do not, said Ronan Kelly of Baylor University Medical Center. The recurrence rate is also high within the first year, Hirawat added.